Merck, 14-773-M, BTK (E41K) Protein, active, 10 µg

General description
Expressed by baculovirus in Sf21 insect cells
N-terminal His6-tagged, recombinant, full-length, human BTK
Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked agammaglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumour suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, .et al., Immunity,(1995);2:451-460 and Baraldi, E., et al., Structure,(1999);7:449-460).
Application
Active, N-terminal His6-tagged, recombinant, full-length, human BTK, for use in Kinase Assays.
Research Category
Inflammation & Immunology
Biochem/physiol Actions
Protein Target: BTK
Target Sub-Family:TK

Packaging
Also available in 250 μg size --call for pricing and availability and reference catalog number 14-773M when ordering the 250 μg size.
Physical form
Format: Ni2+/NTA-agarose
Preparation Note
Store -70°C. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediat
Analysis Note
Routinely evaluated by phosphorylation of LKBtide.
Other Notes
For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial